SABS SAB Biotherapeutics, Inc. - Common Stock
$3.92
Price · Jul 2, 2026
52W Range
$2–$7
45% of range
Analyst Rating
BUY
16 analysts
Price Target
$11
+185% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
SABS Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$3.92
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$2 – $7
SABS Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
SABS
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
SABS
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
SABS
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
SABS
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
SABS
Peer Median
SABS Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
16 analysts
- Strong Buy 7 43.8%
- Buy 8 50.0%
- Hold 1 6.2%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
11 analysts · 2026-07-04
Median
$12.00
Mean
$11.18
← Below all targets
$3.92
Low
$6.00
High
$16.00
Median target
$12.00
+206.1%
Mean target
$11.18
+185.3%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
0.06%
Next Report
Aug 05, 2026
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $-0.35 | $-0.23 | -0.12% |
| Dec. 31, 2025 | $-0.35 | $-0.20 | -0.15% |
| Sept. 30, 2025 | $-0.15 | $-0.52 | 0.37% |
| June 30, 2025 | $-1.09 | $-0.81 | -0.28% |
| March 31, 2025 | $-0.56 | $-1.05 | 0.49% |
Peer Comparison Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| SABS | — | — | — | — | — | — |
| LYEL | $654M | -1.9 | -41.0% | -762355.6% | -100.3% | — |
| RNAC | $188M | -1.4 | -92.8% | -4658.6% | 202.4% | — |
| SRZN | — | — | — | — | — | — |
| FHTX | $306M | -4.6 | 36.8% | -240.3% | 80.2% | — |
| MGNX | $102M | -1.4 | -0.31% | -49.9% | -87.0% | — |
| TRDA | $394M | -3.0 | -87.9% | -565.5% | -41.9% | — |
| GALT | $271M | -8.7 | — | — | 25.0% | — |
| CNXU | — | — | — | — | — | — |
| TLSI | — | — | — | — | — | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.